Regenerative Medical Technology Group Inc.
For the period ended Dec 31, 2025. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed May 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. EXECUTIVE COMPENSATION
| ITEM 11. | EXECUTIVE COMPENSATION. |
|---|
The following summary compensation table sets forth all compensation awarded to, earned by, or paid to the named executive officers paid by us during the years ended December 31, 2025, and 2024.
EXECUTIVE OFFICER COMPENSATION TABLE
| Name and Principal Position · Year · Salary ($) · Bonus ($) · Stock Awards ($) · Option Awards ($) · Non-Equity Incentive Plan Compensation ($) · Non-Qualified Deferred Compensation Earnings ($) · All Other Compensation ($) · Total ($) | ||||
|---|---|---|---|---|
| David Christensen | 2025 | 90,000 | - | 90,000 |
| President, Chief Executive Officer (Principal Executive Officer), Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer), Secretary And Director | 2024 | 90,000 | - | 90,000 |
Outstanding Equity Awards at the End of the Fiscal Year
We do not have any equity compensation plans and therefore no equity awards are outstanding as of December 31, 2025.
None of the members of the board of directors of the Company were compensated for services in such capacity.
Bonuses and Deferred Compensation
We do not have any bonus, deferred compensation or retirement plan. All decisions regarding compensation are determined by our board of directors.
Payment of Post-Termination Compensation
We do not have change-in-control agreements with our director or executive officer, and we are not obligated to pay severance or other enhanced benefits to our executive officer upon termination of her employment.
Employment Agreements
On August 18, 2021, the Company entered into a three-year Consulting Agreement with ETC (Enterprise Technology Consulting), a company owned by David Christensen, the Company’s Chief Executive Officer. Under the terms of the agreement, ETC was compensated at an annual rate of $90,000, payable monthly. In addition, the agreement provided for the issuance of 896 shares of Series DD Preferred Stock of the Company, with 448 shares issued on August 18, 2021, and the remaining 448 shares issued on February 18, 2022.
The original Consulting Agreement expired in August 2024. Following the expiration, the Company has continued to compensate ETC at the same annual rate of $90,000, payable monthly, on a month-to-month basis while finalizing terms for a new agreement.
The Company intends to enter into a new formal consulting agreement with ETC during 2026 to continue these services. This new agreement is expected to maintain similar compensation terms, reflecting the ongoing essential role of Mr. Christensen’s leadership and strategic oversight in the Company’s operations, international expansion, and execution of its regenerative medicine business plan. Any new agreement will be subject to approval by the Board of Directors and will be disclosed in accordance with applicable SEC reporting requirements.
As of the date of this report, no other employment agreements or material compensatory arrangements with executive officers or key personnel have been entered into or modified that require disclosure.
Board of Directors
Our directors hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified. Our officers are elected by and serve at the discretion of the board of directors.
Securities Authorized for Issuance Under Equity Compensation Plans
As of December 31, 2025, we did not have any securities authorized for issuance under any equity compensation plans.
Compensation of Directors
No director received compensation for his services during the year ended December 31, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.